TEVA Teva Pharmaceutical Industries Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: TEVA

Price (delayed)

$11.96

Market cap

$13.11B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.67

Enterprise value

$37.37B

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com

Highlights

Teva Pharmaceutical Industries's EPS has increased by 6% YoY
The debt has declined by 4.5% year-on-year and by 2.2% since the previous quarter
TEVA's quick ratio is down by 14% from the previous quarter but it is up by 11% YoY
Teva Pharmaceutical Industries's equity has decreased by 31% QoQ and by 30% YoY

Key stats

What are the main financial stats of TEVA
Market
Shares outstanding
1.1B
Market cap
$13.11B
Enterprise value
$37.37B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.37
Price to sales (P/S)
0.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.31
Earnings
Revenue
$16.2B
EBIT
-$3.55B
EBITDA
-$1.97B
Free cash flow
$956M
Per share
EPS
-$3.67
Free cash flow per share
$0.87
Book value per share
$8.75
Revenue per share
$14.78
TBVPS
$18.43
Balance sheet
Total assets
$49.74B
Total liabilities
$39.15B
Debt
$26.09B
Equity
$9.59B
Working capital
$57M
Liquidity
Debt to equity
2.72
Current ratio
1
Quick ratio
0.51
Net debt/EBITDA
-12.33
Margins
EBITDA margin
-12.2%
Gross margin
47.1%
Net margin
-24.9%
Operating margin
-24.1%
Efficiency
Return on assets
-7.4%
Return on equity
-31.6%
Return on invested capital
-10.8%
Return on capital employed
-9.4%
Return on sales
-21.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TEVA stock price

How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
4%
1 week
10.84%
1 month
14.56%
1 year
13.47%
YTD
23.94%
QTD
23.94%

Financial performance

How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$16.2B
Gross profit
$7.64B
Operating income
-$3.91B
Net income
-$4.03B
Gross margin
47.1%
Net margin
-24.9%
The operating margin fell by 6% YoY
TEVA's operating income is down by 4.4% YoY
TEVA's gross margin is up by 2.4% YoY
The net margin has declined by 2% year-on-year

Growth

What is Teva Pharmaceutical Industries's growth rate over time

Valuation

What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
1.37
P/S
0.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.31
Teva Pharmaceutical Industries's EPS has increased by 6% YoY
TEVA's price to book (P/B) is 52% higher than its last 4 quarters average of 0.9
Teva Pharmaceutical Industries's equity has decreased by 31% QoQ and by 30% YoY
The P/S is 16% above the last 4 quarters average of 0.7

Efficiency

How efficient is Teva Pharmaceutical Industries business performance
TEVA's ROE is down by 12% YoY
Teva Pharmaceutical Industries's return on assets has decreased by 9% YoY
The company's return on invested capital fell by 8% YoY
Teva Pharmaceutical Industries's return on sales has decreased by 4.8% YoY

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Teva Pharmaceutical Industries financials performed over time
The total assets is 27% greater than the total liabilities
TEVA's quick ratio is down by 14% from the previous quarter but it is up by 11% YoY
The total assets is down by 13% year-on-year and by 10% since the previous quarter
The debt is 172% greater than the equity
TEVA's debt to equity is up by 41% from the previous quarter and by 37% YoY
Teva Pharmaceutical Industries's equity has decreased by 31% QoQ and by 30% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.